Abstract: A method of forming an electrode array includes the steps of positioning a workpiece on a mold part defining an opening and a channel and having undercuts, compressing the workpiece into the mold part to form a contact, and introducing resilient material into the mold part to form a flexible body.

Abstract: A cochlear implant including a cochlear lead, an antenna, a stimulation processor, and a magnet apparatus, associated with the antenna, including a case defining a central axis, a magnet frame within the case and rotatable about the central axis of the case, and a plurality of elongate diametrically magnetized magnets that are located in the magnet frame, the magnets defining a longitudinal axis and a N-S direction and being freely rotatable about the longitudinal axis relative to the magnet frame.

Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.

Abstract: The present disclosure relates to cleavable carriers and cleavable carrier-linked cytokine prodrugs wherein the cleavable carrier is an engineered Fc domain comprising at least one tumor-associated protease cleavage site. Upon cleavage at the cleavage site of the carrier Fc domain, the cytokine is released from a masking moiety. The platform provides enzymatically induced prodrug activation. The present disclosure further provides pharmaceutical compositions comprising said cleavable carrier-linked cytokine prodrugs, their use as a medication as well as methods of treatment of diseases and administration.

Abstract: Provided is a method for controlling a wind power installation, the wind power installation having a generator for the generation of electric current, the generator having an air gap with a variable air gap thickness, the wind power installation being controlled in a part load range by means of a control regulation, the wind power installation being controlled in a manner which is dependent on the air gap thickness, the control regulation being selected or set in a manner which is dependent on the air gap width.

Abstract: The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.

Abstract: A method and a device for operating an assistance system of a vehicle involves detecting laterally static and laterally dynamic objects, which the vehicle is to drive past, as lateral boundary objects. A respective lateral distance of the vehicle from the respective lateral boundary object is detected. A speed of the respective laterally dynamic object is determined and at least the respectively laterally dynamic object is classified according to its type. A set of characteristic curves is stored in a control unit of the vehicle, the characteristic curves of the set being assigned in each case to an environmental situation predetermined depending on lateral boundary objects. It is predetermined by a respective characteristic curve for the respective environmental situation at what maximum speed the vehicle is to drive past a lateral boundary object at different lateral distances from the latter.

Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.

Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).

Abstract: The invention relates to the treatment or prevention of renal impairment and/or complications using a SGLT-2 inhibitor, for example in patients diagnosed with metabolic disorders and related conditions.

Abstract: In some embodiments, an electronic device receives, via one or more input devices, an input corresponding to a request to display a user interface associated with a first respective content mix, wherein the first respective content mix is associated with a first respective time period. In some embodiments in response to receiving the input corresponding to the request to display the user interface associated with the first respective content mix, the electronic device displays, via a display, the user interface. In some embodiments, the user interface includes a plurality of representations of content items including visual indications of amounts of consumption, of a first consumption metric type, by a user during the first respective time period, and a plurality of representations of content creators including visual indications of consumption, of a second consumption metric type, by the user during the first respective time period.

Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).

Abstract: Systems and methods include receiving a request for resources that are one of web content and a cloud application from a user device; determining the request requires isolation based on any of policy, category of the web content, type of the user device, and location of the user device; rendering content associated with the request in a secure environment that is isolated from the user device; and providing image content based on the content to the user device. The user device can execute a web browser that loads the image content utilizing a JavaScript application and that interacts with the image content by sending keyboard and mouse inputs via a WebSocket channel.

Abstract: In some embodiments, an electronic device presents information about a function of an application and facilitates performance of functions of the application. The information is optionally displayed in response to receiving an input to perform an action associated with the respective function when information-display criteria are met. In some embodiments, the criteria include a criterion that is satisfied when the respective function has not yet been initiated by the user on the electronic device.

Abstract: The present invention relates to targeted, masked cytokines, comprising a cytokine or functional fragment thereof, a masking moiety, a targeting moiety and a proteolytically cleavable linker. The targeting moiety comprises an antigen-binding moiety that specifically binds to an antigen expressed on the surface of a target cell The masking moiety masks the cytokine or functional fragment thereof thereby reducing or preventing binding of the cytokine or functional fragment thereof to its cognate receptor, but upon proteolytic cleavage of the cleavable linker at a target site, the cytokine or functional fragment thereof becomes activated, which renders it capable or more capable of binding to its cognate receptor.

Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.

Abstract: Disclosed are methods and compositions for the treatment of facioscapulohumeral muscular dystrophy. In some cases, the methods and compositions involve the use of kinase inhibitors include Src, Syk, Abl, Tie, Flt, ErbB, Trk, PRKDC, and Yes families to repress DUX4 expression in muscle cells. Further disclosed are methods and cell based assays for screening compounds for the treatment of facioscapulohumeral muscular dystrophy.

Abstract: Generating a customized playlist may include identifying a user account for which a playlist is to be generated, where the user account is associated with a user listening history, a taste profile, and a social profile, identifying one or more friend accounts linked to the user account based on the social profile, obtaining an indication of a plurality of songs associated with one or more of the friend accounts, determining a listening history for the one or more plurality of songs based on the friend accounts, obtaining a subset of the plurality of songs based on the listening history of the plurality of songs, and generating a playlist from the subset of the plurality of songs.

Abstract: The invention relates to a digital access system (1), an electric vehicle (100) with such an access system and a method (200) for granting an access authorization to an electric vehicle with such an access system, comprising an unlocking unit (11) for positioning in the vehicle (100), at least one access unit (12) and at least one activation unit (13) for use outside the vehicle (100), wherein the activation unit (13) activates the unlocking unit (11) by means of wireless data communication (21) to the unlocking unit (11) at least for a period, the access unit (12) arranging access arranging access to the vehicle (100) from the outside by means of an independent wireless data communication (22) separate to the previous data communication (21) with the previously activated receiving unit (11), wherein the unlocking unit (11) transmits control signals (14) to the system controller (110) in response to the data communication (22) with the access unit (12) for controlling the locking system and activating at leas